MBody AI Ltd. (MBAI)
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Last price
- $2.04
- As of
Kresmion compiles this page from MBAI's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
MBody AI Ltd. (MBAI): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-22.
See the full MBAI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MBAI on one page. Preview it with sample data, then open it live with a free account.
Preview the MBAI dossierActive events for MBAI
- medium13F: new position
CITADEL ADVISORS LLC new position in MBAI
- mediumEarnings below estimates
Q2-2023: Missed consensus by 104.8% - EPS $-0.94 vs $-0.459 estimate
- mediumEarnings above estimates
Q4-2022: Beat consensus by 8.4% - EPS $-0.635 vs $-0.6936 estimate
- mediumEarnings below estimates
Q1-2023: Missed consensus by 36.7% - EPS $-0.76 vs $-0.5559 estimate
- mediumEarnings below estimates
Missed consensus by 104.8% - EPS $-0.94 vs $-0.459 estimate
FREE, NO ACCOUNT
Every event on MBAI, as it fires
You are seeing 5 of 6 events recorded on MBAI since 2026-06-04.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, MBAI
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
MBAI against its peers
MBAI's return on equity of 120.5% ranks in the 97th percentile of 14 Diagnostics & Research sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | MBAI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 34.0M | n/a | 18 |
| Gross margin | n/a | 56.7% | n/a | 13 |
| Operating margin | n/a | -34.7% | n/a | 17 |
| Net margin | n/a | -34.5% | n/a | 18 |
| Return on equity | 120.5% | -15.4% | 97 | 14 |
Peers (21): IDXG, PRPO, MDXH, LDDD, QUCY, IMDX, XWEL, NDRA, AWHL, FONR.D, BNR, ADVB, BDSX, ISPC, OPK, NSTM, PSNL, FUNI, NEO, CDNA, PRPH. Left out: ANPCF (no annual filing), PMDI (period gap), BIAF (no annual filing), NOTV.D (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (MBAI: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow MBAI on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to MBAI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.